Ocugen Faces Delisting Concerns

TL;DR

Ocugen might get delisted, filing shows.

AI Summary

Ocugen, Inc. filed an 8-K on January 3, 2025, reporting a Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard as of December 31, 2024. The company, incorporated in Delaware, is based in Malvern, Pennsylvania.

Why It Matters

This filing indicates potential issues with Ocugen's compliance with stock exchange listing requirements, which could lead to its shares being delisted.

Risk Assessment

Risk Level: high — A notice of delisting or failure to meet listing standards poses a significant risk to the company's stock trading status.

Key Numbers

• 001-36751 — SEC File Number (Identifies the company's filing history with the SEC.)
• 04-3522315 — I.R.S. Employer Identification Number (Company's tax identification number.)

Key Players & Entities

• Ocugen, Inc. (company) — Registrant
• Delaware (jurisdiction) — State of Incorporation
• Malvern, Pennsylvania (location) — Principal Executive Office
• December 31, 2024 (date) — Date of Earliest Event Reported
• January 3, 2025 (date) — Filing Date

FAQ

Key Financial Figures

• $0.01 — nge on which registered Common Stock, $0.01 par value per share OCGN The Nasdaq
• $1.00 — common stock has been below the minimum $1.00 per share required for continued listin
• $1 m — lue of publicly held shares of at least $1 million, meets all other initial listing

Filing Documents

• tm251676d1_8k.htm (8-K) — 28KB
• 0001104659-25-000827.txt ( ) — 197KB
• ocgn-20241231.xsd (EX-101.SCH) — 3KB
• ocgn-20241231_lab.xml (EX-101.LAB) — 33KB
• ocgn-20241231_pre.xml (EX-101.PRE) — 22KB
• tm251676d1_8k_htm.xml (XML) — 3KB

01 Notice of Delisting or Failure to Satisfy a Continued

Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. On December 31, 2024 Ocugen, Inc. (the "Company") received a notification letter (the "Bid Price Letter") from The Nasdaq Stock Market LLC ("Nasdaq") notifying the Company that, for the last 30 consecutive business days, the closing bid price for the Company's common stock has been below the minimum $1.00 per share required for continued listing on The Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5550(a)(2) ("Rule 5550(a)(2)"). The Bid Price Letter is a notice of deficiency, not delisting, and does not currently affect the listing or trading of the Company's shares of common stock on The Nasdaq Capital Market. The Company has 180 days, or until June 30, 2025, to comply with Rule 5550(a)(2) by maintaining a closing bid price of at least $1.00 per share for 10 consecutive business days. Additionally, the Company may be eligible for a second 180-day period to satisfy Rule 5550(a)(2), if, as of June 30, 2025, the Company continues to have a market value of publicly held shares of at least $1 million, meets all other initial listing standards of The Nasdaq Capital Market (with the exception of the bid price requirement), and provides written notice of its intention to cure the deficiency during such second compliance period. The Company intends to monitor closely the closing bid price of its common stock and to consider plans for regaining compliance with Rule 5550(a)(2). While the Company plans to review all available options, there can be no assurance that it will be able to regain compliance with the applicable rules during the 180-day compliance period, any subsequent extension period, or at all.

Forward-Looking Statements

Forward-Looking Statements In addition to historical information, this Report contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act, and Section 21E of the Exchange Act. Such forward-looking statements include statements regarding the Company's intent or ability to regain compliance with Nasdaq's minimum bid price requirement and other statements that are not statements of historical fact. In some cases these statements may be identified by words like "anticipate," "assume," "believe," "continue," "could," "estimate," "expect," "intend," "may," "plan," "potential," "predict," "project," "future," "will," "should," "would," "seek," and similar terms or phrases. Important factors that could cause the Company's actual results to differ materially from those indicated in the forward-looking statements are more fully discussed in the Company's periodic filings with the Securities and Exchange Commission (the "SEC"), including the risk factors described under the heading "Risk Factors" in the Company's Annual Report on Form 10-K for the year ended December 31, 2023 filed with the SEC and other documents subsequently filed with or furnished to the SEC. Any forward-looking statement made in this Report speaks only as of the date hereof. Except as required by law, the Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future developments, or otherwise. 1 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: January 3, 2025 OCUGEN, INC. By: /s/ Shankar Musunuri Name: Shankar Musunuri Title: Chairman, Chief Executive Officer, & Co-Founder 2

View Full Filing

View this 8-K filing on SEC EDGAR